Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences has demonstrated a strong commitment to advancing its oncology-focused precision medicine portfolio, particularly with darovasertib, which has shown promising efficacy and safety in early and ongoing clinical trials. The company is in the midst of two Phase 3 trials while also pushing forward with multiple catalysts that could enhance its revenue potential, projected to reach approximately $3.2 billion from its leading assets. With compelling data evidencing significant patient improvement and a favorable risk-adjusted probability of success, IDEAYA’s strategic initiatives position it for substantial growth in a high-value sector.

Bears say

IDEAYA Biosciences faces significant financial uncertainties due to unpredictability in future revenues and expenses alongside its non-revenue-generating status, leading to stock price volatility that may not align with current valuations. Potential negative outcomes from clinical trials, such as disappointing readouts and slower enrollment, could hinder commercialization efforts and reduce the market potential of its product candidates like IDE397 and IDE849. Furthermore, challenges regarding intellectual property protection and unclear pathways to commercialization create additional risks that may diminish investor confidence and hinder the company’s competitive positioning in the oncology market.

IDYA has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 11 analysts, IDYA has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.